MindWalk (NASDAQ: HYFT) Files Patent for High-Dimensional Biological Data Architecture Powering AI Drug Discovery

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

• As AI models become more broadly available, lasting advantage in life sciences will come from the biological context those models can use; the differentiator is the structured biological representation that lets models and agentic workflows retrieve connected evidence, preserve provenance, and reuse knowledge across programs. The filing is intended to protect aspects of the architecture at the core of HYFT Technology, where MindWalk believes lasting value in biological AI can compound.

  60% confidence

• EP26187897.9 protects a distinct and additive layer to MindWalk's foundational HYFT patent (EP3881326A1) — organizing the biological meaning around identified biological patterns into a form reusable across MindWalk's infrastructure, customer programs, and AI workflows. It is a computational layer built on the original foundation, not a re-filing of it.

  60% confidence

Cited in these Via News reports

• Denmark's Novo Nordisk Outsources Drug R&D as US Firms Patent the AI Layer Beneath Biology →
• MindWalk's Biology Database Hits 660 Million Patterns as Pharma Outsources Drug R&D →
• NVIDIA GPU Power Fuels Global Boom in AI Drug Discovery Startups →
• NVIDIA's BioNeMo Locks In Thermo Fisher, Eli Lilly as Global Pharma Shifts to Shared AI Platforms →